N-Benzyl-2-phenylindoles as estrogenic agents

Abstract: The present invention relates to new 3-[4-(2-Phenyl-Indole-1-ylmethyl)-Phenyl]-Acrylamide compounds and new 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, the compounds having the general formulas, below: wherein Z is selected from or -C≡C-(CH 2 ) n -Y.

Description: The present invention relates to new 3-[4-(2-Phenyl-Indole-1-ylmethyl)-Phenyl]-Acrylamide compounds and new 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds. Background of the invention The use of hormone replacement therapy for bone loss prevention in post-menopausal women is well precedented. The normal protocol calls for estrogen supplementation using such formulations containing estrone, estriol, ethynyl estradiol or conjugated estrogens isolated from natural sources (Premarin from Wyeth-Ayerst). In some patients, therapy may be contraindicated due to the proliferative effects unopposed estrogens (estrogens not given in combination with progestins) have on uterine tissue. This proliferation is associated with increased risk for endometriosis and/or endometrial cancer. The effects of unopposed estrogens on breast tissue is less clear, but is of some concern. The need for estrogens which can maintain the bone sparing effect while minimizing the proliferative effects in the uterus and breast is evident. Certain nonsteroidal antiestrogens have been shown to maintain bone mass in the ovariectomized rat model as well as in human clinical trials. Tamoxifen, for example, is a useful palliative for the treatment of breast cancer. It has been demonstrated to exert an estrogen agonist like effect on the bone, in humans. However, it is also a partial agonist in the uterus and this is cause for some concern. Raloxifene, a benzothiophene antiestrogen, has been shown to stimulate uterine growth in the ovariectomized rat to a lesser extent than Tamoxifen while maintaining the ability to spare bone. A suitable review of tissue selective estrogens is: Tissue -Selective Actions Of Estrogen Analogs, Bone Vol. 17, No. 4, October 1995, 181S-190S. The use of indoles as estrogen antagonists has been reported by Von Angerer, Chemical Abstracts, Vol. 99, No. 7 (1983), Abstract No. 53886u. Also, see, J.Med.Chem. 1990, 33, 2635-2640; J.Med.Chem. 1987, 30, 131-136. Also see Ger. Offen., DE 3821148 A1 891228 and WO 96/03375. Additionally, see WO, A, 93 23374 (Otsuka Pharmaceutical Factory, Inc.). Von Angerer's work is limited to aliphatic chains linked to the indole nitrogen and then linked to the basic amine (or amide) or, benzyl groups not possessing the basic amine. The world patent from Otsuka (Japanese) consists of compounds related to the present invention except R 3 (as shown in formula I) is defined as -SR where R is alkyl. Additionally, there are no chains from the indole nitrogen in their patent with the same structure as the ones given in the present invention, either by claim or example. A related patent WO A 93 10741 describes 5-Hydroxyindoles. WO A 95 17383 (Kar Bio AB) describes aliphatic chain compounds. WO A 95 17383 (Karo Bio AB) describes indole antiestrogens with long straight chains. Another related patent WO A 93 10741 describes 5-hydroxyindoles with a broad range of side chains. WO 93/23374 (Otsuka Pharmaceuticals, Japan) describes compounds sharing structural similarities with those of the present invention, except with the structure referred to as R 3 in the present formulas I and II, below, is defined as thioalkyl and the reference discloses no such compounds having chains from the indole nitrogen having the same structure as the ones provided by the present invention. Description of the Invention Compounds of the general structure type shown in formulas (I) and (II) are estrogen agonists/antagonists useful for the treatment of diseases associated with estrogen deficiency. The compounds of the present invention show strong binding to the estrogen receptor. These compounds have proven to be antiestrogens with little intrinsic estrogenicity. In a three-day ovariectimized rat model, compounds of formula (I) are capable of antagonizing the effects of 17β- estradiol while showing little uterine stimulation when dosed alone. The present invention includes compounds of formulas (I) and (II), below: wherein: R 1 is selected from H, OH or the C 1 -C 4 esters or alkyl ethers thereof, or halogen; R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from H, OH or the C 1 -C 4 esters or alkyl ethers thereof, halogen, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; n is 2 or 3; X is selected from H, C 1 -C 6 alkyl, cyano, nitro, trifluoromethyl, halogen; Z is selected from Y is selected from: a) the moiety wherein R 7 and R 8 are independently selected from the group of H, C 1 -C 6 alkyl, phenyl or combined by -(CH 2 ) p -, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, -CO 2 H, -CN, -CONH(C 1 -C 4 )alkyl, -NH 2 , C 1 -C 4 alkylamino, di-(C 1 -C 4 alkyl)amino, -NHSO 2 (C 1 -C 4 )alkyl, -NHCO(C 1 -C 4 )alkyl and -NO 2 ; b) a five-, six-, or seven-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C 1 -C 4 alkyl)-, -N=, and -S(O) m -, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 acyloxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy(C 1 -C 4 )alkyl, -CO 2 H, -CN, -CONHR 1 , -NH 2 , (C 1 -C 4 )alkylamino, di-(C 1 -C 4 alkyl)amino, -NHSO 2 R 1 , -NHCOR 1 , -NO 2 and phenyl optionally substituted with from 1 to 3 (C 1 -C 4 )alkyl groups; c) a bicyclic ring system consisting of a five or six-membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group of -O-, -NH-, -N(C 1 -C 4 alkyl)-, and -S(O) m -, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 acyloxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, -CO 2 H, -CN, -CONHR 1 , -NH 2 , (C 1 -C 4 )alkylamino, di-(C 1 -C 4 alkyl)amino, -NHSO 2 R 1 , -NHCOR 1 , -NO 2 and phenyl optionally substituted with from 1 to 3 (C 1 -C 4 )alkyl groups; and the pharmaceutically acceptable salts thereof. The rings formed by a concatenated R 7 and R 8 , mentioned above, may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, or hexamethyleneamine rings. It is further preferred that, when R 7 and R 8 are concatenated together as -(CH 2 ) p -, the ring so formed is optionally substituted with 1-3 substituents selected from a group containing C 1 -C 3 alkyl, trifluoromethyl, halogen, phenyl, nitro and -CN. The most preferred compounds of the present invention are those having the structural formulas I or II, above, wherein R 1 is OH; R 2 - R 6 are as defined above; X is selected from the group of Cl, NO 2 , CN, CF 3 , or CH 3 ; and Y is the moiety and R 7 and R 8 are concatenated together as -(CH 2 ) p -, wherein p is an integer of from 4 to 6, to form a ring optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, -CO 2 H, -CN, -CONH(C 1 -C 4 )alkyl, -NH 3 , (C 1 -C 4 )alkylamino, di(C 1 -C 4 )alkylamino, -NHSO 2 (C 1 -C 4 )alkyl, -NHCO(C 1 -C 4 )alkyl, and -NO 2 ; and the pharmaceutically acceptable salts thereof. The invention includes acceptable salt forms formed from the addition reaction with either inorganic or organic acids. Inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, nitric acid useful as well as organic acids such as acetic acid, propionic acid, citric acid, maleic acid, malic acid, tartaric acid, phthalic acid, succinic acid, methanesulfonic acid, toluenesulfonic acid, napthalenesulfonic acid, camphorsulfonic acid, benzenesulfonic acid are useful. It is known that compounds possessing a basic nitrogen can be complexed with many different acids (both protic and not protic) and usually it is preferred to administer a compound of this invention in the form of an acid addition salt. The compounds of the invention are partial estrogen agonists and display high affinity for the estrogen receptor. Unlike many estrogens, however, these compounds do not cause increases in uterine wet weight. These compounds are antiestrogenic in the uterus and can completely antagonize the trophic effects of estrogen agonists in uterine tissue. These compounds are useful in treating or preventing mammal disease states or syndromes which are caused or associated with an estrogen deficiency. The present compounds have the ability to behave like estrogen agonists by lowering cholesterol and preventing bone loss. Therefore, these compounds are useful for treating many maladies including osteoporosis, prostatic hypertrophy, infertility, breast cancer, endometrial cancer, cardiovascular disease, contraception, Alzheimer's disease and melanoma. Additionally, these compounds can be used for hormone replacement therapy in post-menopausal women or in other estrogen deficiency states where estrogen supplementation would be beneficial. The compounds of this invention may also be used in medicaments for the treatment for bone loss, which may result from an imbalance in an individual's formation of new bone tissues and the resorption of older tissues, leading to a net loss of bone. Such bone depletion results in a range of individuals, particularly in post-menopausal women, women who have undergone hysterectomy, those receiving or who have received extended corticosteroid therapies, those experiencing gonadal dysgenesis, and those suffering from Cushing's syndrome. Special needs for bone replacement can also be addressed using these compounds in individuals with bone fractures, defective bone structures, and those receiving bone-related surgeries and/or the implantation of prosthesis. In addition to those problems described above, these compounds can be used in treatments for osteoarthritis, Paget's disease, osteomalacia, osteohalisteresis, endometrial cancer, multiple myeloma and other forms of cancer having deleterious effects on bone tissues. Treating the maladies listed herein is understood to comprise administering to an individual in need of such treatment a pharmaceutically effective amount of one or more of the compounds of this invention or a pharmaceutically acceptable salt thereof. This invention also includes pharmaceutical compositions utilizing one or more of the present compounds, and/or the pharmaceutically acceptable salts thereof, along with one or more pharmaceutically acceptable carriers, excipients, etc. It is understood that the dosage, regimen and mode of administration of these compounds will vary according to the malady and the individual being treated and will be subjected to the judgment of the medical practitioner involved. It is preferred that the administration of one or more of the compounds herein begins at a low dose and be increased until the desired effects are achieved. Effective administration of these compounds may be given at a dose of from about 0.1 mg/day to about 1,000 mg/day. Preferably, administration will be from about 50 mg/day to about 600 mg/day in a single dose or in two or more divided doses. Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, parenterally (including intravenous, intraperitoneal and subcutaneous injections), and transdermally. For the purposes of this disclosure, transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal). Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s). Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of various molecular weights, may also be used. This invention also provides a process for preparing a compound of formula I which comprises one of the following: a) reacting a compound of formula wherein R 1 -R 6 and X are as defined above with an acrylamide of formula wherein Y is as defined above to give a compound of formula I wherein Z is -CH=CH-COY; or b) reacting a compound of formula wherein R 1 -R 6 and X are as defined above with a compound of formula wherein n and Y are as defined above to give a corresponding compound of Formula I wherein Z is ―C≡C―(CH 2 ) n ―Y. Conveniently compounds of this invention can be synthesized in a general sense according to Schemes 1 and 2, below. The initial indole synthesis of Scheme 1 is accomplished by heating an appropriately substituted aniline (1) with an appropriately substituted alpha-bromophenylpropriophenone (2) in a suitably high boiling solvent such as DMF. The product is then alkylated with a 4-bromobenzyl bromide to give the substituted indole (3). At this point, deprotection of phenols (if present) is done. Normally, the phenols are protected as benzyl ethers and can conveniently be cleaved with TMSI. The acrylamides are coupled using Heck reaction conditions in either neat Et 3 N or Et 3 N/CH 3 CN. The initial indole synthesis of Scheme 2 may be accomplished by heating an appropriately substituted aniline (1) with an appropriately substituted alpha-bromophenylalkyl-phenone (2) in a suitably high boiling solvent such as DMF. The product is then alkylated with 4-iodobenzyl bromide to give the substituted indole (3). At this point, deprotection of phenols (if present) is done. Normally, the phenols are protected as benzyl ethers and can conveniently be cleaved with TMSI. The propargylamines can then be coupled to the phenyl iodide. The propargylamines are typically prepared from an alkynyl bromide or alkynyl tosylate by substitution with the appropriate amine. The substitution reaction is done in situ, without isolating the propargylamine. Compounds substituted at the 3-position with groups other then alkyl may be prepared by first preparing the indole substituted at the 3- position with -H. The indole can then be electrophilically halogenated, formylated, etc., to give other 3-substituted compounds. Solvents used for the reactions herein were anhydrous Aldrich Sure Seal™ without further purification. Reagents were typically Aldrich and used without further purification. All reactions were carried out under a nitrogen atmosphere. Chromatography was performed using 230-400 mesh silica gel (Merck Grade 60, Aldrich Chemical Company). Thin layer chromatography was performed with Silica Gel 60 F 254 plates from EM Science. 1 H NMR spectra were obtained on a Bruker AM-400 instrument in DMSO and chemical shifts reported in ppm. Melting points were determined on a Thomas-Hoover apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer diffraction grating or Perkin-Elmer 784 spectrophotometers. Mass spectra were recorded on a Kratos MS 50 or Finnigan 8230 mass spectrometers. Elemental analyses were obtained with a Perkin-Elmer 2400 elemental analyzer. Analysis values are within 0.4 % of theoretical. The present invention is further illustrated by the following non-limiting examples. EXAMPLE 1 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1H-indole A flask was charged with 4-benzyloxyaniline (45 g, 0.23 mol), 4'-benzyloxy-2-bromophenylpropiophenone (21g, 0.066 mol), and DMF (50 mL). The reaction was heated at reflux for 30 minutes and then cooled to rt and then partitioned between EtOAc (250 mL) and 1N HCl (aq) (100 mL). The EtOAc was washed with NaHCO 3 (aq) and brine, dried over MgSO 4 . The solution was concentrated and the residue taken up in CH 2 Cl 2 and hexanes added to precipitate out 25g of a crude solid. The solid was dissolved in CH 2 Cl 2 and evaporated onto silica gel and chromatographed using CH 2 Cl 2 /Hexane (1:5) to yield 9.2 g of a tan solid (33%): Mpt = 150-152°C; 1 H NMR (DMSO) 10.88 (s, 1 H), 7.56 (d, 2 H, J = 8.8 Hz), 7.48 (d, 4 H, J = 7.9 Hz), 7.42-7.29 (m, 6 H), 7.21 (d, 1 H, J = 7.0 Hz), 7.13 (d, 2 H, J = 8.8 Hz), 7.08 (d, 1 H, J = 2.2 Hz), 6.94 (dd, 1 H, J = 8.8, 2.4 Hz), 5.16 (s, 2 H), 5.11 (s, 2 H), 2.33 (s, 3 H); IR (KBr) 3470, 2880, 2820, 1620 cm -1 ; MS eI m/z 419. EXAMPLE 2 5-Benzyloxy-2-(4-fluoro-phenyl)-3-methyl)-1H-indole The title compound was prepared similarly to (3): MP=132°C; 1 H NMR (DMSO) 11.0 (s, 1 H), 7.68-7.64 (m, 2 H), 7.49-7.47 (m, 2 H), 7.41-7.31 (m, 5 H), 7.23 (d, 1 H, J = 8.8 Hz), 7.10 (d, 1 H, J = 2.4 Hz), 6.82 (dd, 1 H, J = 8.8, 2.4 Hz), 5.11 (s, 2 H), 2.34 (s, 3 H); MS EI m/z 331; CHN calcd for C 22 H 18 FNO. EXAMPLE 3 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl)-1-ylmethyl-(4-phenylbromide)-indole A solution of 60% NaH (0.17g, 7.1 mmol) in DMF (20 mL) was cooled to 0°C and treated by dropwise addition of benzyloxyindole 1 (2.5g, 5.94 mmol) in DMF (10 mL). After 15 min, 4'-bromobenzylbromide (1.63g, 6.53 mmol) in DMF (10 mL) was added dropwise. The reaction was stirred for 5 min at 0°C and then at rt for an additional 20 min. The reaction mixture was diluted with ether (300 mL) and washed with NH 4 Cl (2x25 mL) then NaHCO 3 (1x25 mL), and brine (25 mL). The organic extracts were dried over MgSO 4 and concentrated. The residue was crystallized from THF/Hexanes to yield 2.7 g (77%) of 2 : Mp=144-146°C; 1 H NMR (CDCl 3 ) 7.51-7.36 (m, 8 H), 7.34 (d, 4 H, J = 8.6 Hz), 7.20 (d, 2 H, J = 8.8 Hz), 7.15 (d, 1 H, J = 2.4 Hz), 7.03-7.00 (m, 3 H), 6.89 (dd, 1 H, J = 8.8, 2.4 Hz), 6.80 (d, 2 H, J = 8.6 Hz), 5.14 (s, 2 H), 5.12 (s, 2 H), 5.09 (s, 2 H), 2.25 (s, 3 H); IR (KBr) 3400, 3020, 1600 cm -1 ; MS eI m/z 587. EXAMPLE 4 5-Benzyloxy-2-(4-fluoro-phenyl)-3-methyl)-1-ylmethyl-(4-phenylbromide)-indole The title compound was prepared similarly to compound 5 . Mp=139-139.5°C; 1H NMR (DMSO) 7.49-7.46 (m, 2 H), 7.41-7.37 (m, 6 H), 7.33-7.27 (m, 4 H), 7.24 (d, 1 H, J = 8.8 Hz), 7.16 (d, 1 H, J = 2.2 Hz), 6.84 (dd, 1 H, J = 8.8, 2.4 Hz), 6.73 (d, 1 H, J = 8.6 Hz), 5.2 (s, 2 H), 5.12 (s, 2 H), 2.15 (s, 3 H); IR (KBr) 2920, 1630 cm -1 ; MS eI m/z (499/501, Br present); CHN calcd for C 29 H 23 BrFNO. EXAMPLE 5 2-(4-hydroxyphenyl)-3-methyl)-1-ylmethyl-(4-phenylbromide)-indole-5-ol A solution consisting of 5 (0.5 g, 0.85 mmol) in CH 2 Cl 2 (10 mL) was treated with by dropwise addition of 3.5 eq TMSI (0.47 mL, 3.0 mmol) at rt. After a couple hours, the reaction stopped so an additional 2.2 eq TMSI was added and the reaction heated to reflux for 5 h. The reaction was cooled to 0°C and methanol slowly added to quench the reaction. The reaction was diluted with ether (25 mL) and washed with NaHCO 3 (25 mL), 10 % Na 2 SO 3 (25 mL), and brine. The ether layer was dried over MgSO 4 and concentrated onto silica gel. Chromatography with EtOAc/Hexanes (1:4 to 1:1) yielded 0.25 g 3 (71%): Mp=83-86°C; 1 H NMR (CDCl 3 ) 2 H's from phenols broad (> 10),s 7.35 (d, 2 H, J = 9.0 Hz), 7.15 (d, 2 H, J = 8.8 Hz), 7.01 (dd, 1 H, J = 2.4, 0.4 HZ), 6.86 (d, 2 H, J = 8.8 HZ), 6.80 (d, 1 H, J = 8.6 Hz), 6.72 (dd, 1 H, J = 8.6, 2.4 Hz), 5.10 (s, 2 H), 4.88 (s, 1 H), 4.50 (s, 1 H), 2.21 (s, 3 H); MS eI m/z 407/409 contains Br; IR 3390, 2900, 1600 cm -1 ; CHN calc'd for C 22 H 18 BrNO 2 + 0.25 EtOAc. EXAMPLE 6 2-(4-fluoro-phenyl)-3-methyl)-1-ylmethyl-(4-phenylbromide)-indole-5-ol The title compound was prepared similarly to compound 7 and isolated as a foam. 1 H NMR (DMSO) 8.79 (s, 1 H), 7.39-7.34 (m, 4 H), 7.32-7.30 (m, 3 H), 7.11 (d, 1 H, J = 8.8 Hz), 6.85 (d, 1 H, J = 2.2 Hz), 6.74 (d, 1 H, J = 2.4 Hz), 6.63 (dd, 1 H, J = 8.6, 2.2 Hz), 5.16 (s, 2 H), 2.11 (s, 3 H); IR (KBr) 3400, 2900, 1630 cm -1 ; MS eI m/z 409/411 contains Br. General Procedure For Indole Acrylamides A solution of example 3 in Et 3 N is treated with tri-o-tolylphosphine (10 mol%), and acrylamide (1.25 eq) is purged thoroughly with N 2 and Pd(OAc) 2 (2.5 mol%) added. The reaction is heated at 100-110°C in a sealed tube until completed by TLC analysis. The crude reaction product is concentrated down and either crystallized directly or chromatographed on silica gel. EXAMPLE 7 (E)-N, N-Diethyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=160-165°C; 1 H NMR 9.67 (s, 1 H), 8.72 (s, 1 H), 7.50 (d, 2 H, J = 8.1 Hz), 7.37 (d, 1 H, J = 15.4 Hz), 7.17 (d, 2 H, J = 8.3 Hz), 7.06 (d, 1 H, J = 8.8 Hz), 6.97 (d, 2 H; J = 15.4 Hz), 6.86-6.82 (m, 5 H), 6.58 (dd, 1 H, J = 8.6, 2.2 Hz), 5.19 (br s, 2 H), 3.47-3.42 (m, 2 H), 3.34-3.30 (m, 2 H), 2.09 (s, 3 H), 1.10 (t, 3 H, J = 7.0 Hz), 1.03 (t, 3 H, J = 7.0 Hz); IR (KBr) 3300, 2950, 1660, 1580 cm -1 ; MS (eI) m/z 454; CHN calc'd for C 29 H 30 N 2 O 3 +0.15 CH 2 Cl 2 + 0.30 H 2 O. EXAMPLE 8 1(E)-N-tert-butyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=168-170°C; 1 H NMR 9.66 (s, 1 H), 8.71 (s, 1 H), 7.66 (s, 1 H), 7.34 (d, 2 H, J = 8.3 Hz), 7.24 (d, 1 H, J = 15.8 Hz), 7.15 (d, 2 H, J = 8.3 Hz), 7.05 (d, 1 H, J = 8.6 Hz), 6.85-6.82 (m, 5 H), 6.59-6.56 (m, 1 H), 6.55 (d, 1 H, J = 16.0 Hz), 5.18 (s, 2 H), 2.11 (s, 3 H), 1.28 (s, 9 H); IR (KBr) 3350, 2950, 1660, 1620; MS (eI) m/z 454; CHN calc'd for C 29 H 30 N 2 O 3 + 0.4H 2 O EXAMPLE 9 (E)-Pyrrolidino-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=170-175°C; 1 H NMR 9.67 (s, 1 H), 8.71 (s, 1 H), 7.49 (d, 2 H, J = 8.1 Hz), 7.35 (d, 1 H, J = 15.4 Hz), 7.16 (d, 2 H, J = 8.6 Hz), 7.05 (d, 1 H, J = 8.8 Hz), 6.88-6.81 (m, 6 H), 6.57 (dd, 1 H, J = 8.6, 2.2 Hz), 5.19 (br s, 2 H), 3.56 (t, 2 H, J = 6.6 Hz), 3.35 (m, 2 H), 2.11 (s, 3 H), 1.87 (p, 2 H, J = 7.0 Hz), 1.77 (p, 2 H, J = 7.0 Hz); MS m/z 452; CHN calc'd for C 29 H 28 N 2 O 3 + 0.1 MeOH + 1.3 H 2 O. EXAMPLE 10 (E)-N, N-Dimethyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=278-280°C; 1 H NMR (DMSO) 9.65 (s, 1 H), 8.70 (s, 1 H), 7.50 (d, 2 H, J = 8.1 Hz), 7.33 (d, 1 H, J = 15.4 Hz), 7.15 (d, 2 H, J = 8.6 Hz), 7.07 (d, 1 H, J = 15.6 Hz), 7.05 (d, 1 H, J = 8.8 Hz), 6.85-6.80 (m, 5 H), 6.57 (dd, 1 H, J = 8.6, 2.4 Hz), 5.19 (s, 2 H), 3.09 (s, 3 H), 2.88 (s, 3 H), 2.11 (s, 3 H); MS eI m/z 426; IR (KBr) 3410, 3220, 1650, 1580 cm -1 ; CHN calc'd for C 27 H 26 N 2 O 3 + 0.5 H 2 O. EXAMPLE 11 (E)-N, N-Dibutyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=126-128°C, 1 H NMR (DMSO) 9.65 (s, 1 H), 8.70 (s, 1 H), 7.48 (d, 2 H, J = 8.3 Hz), 7.36 (d, 1 H, J = 15.2 Hz), 7.16 (d, 2 H, J = 8.6 Hz), 7.05 (d, 1 H, J = 8.6 Hz), 6.97 (d, 1 H, J = 15.2 Hz), 6.86-6.81 (m, 5 H), 6.57 (dd, 1 H, J = 8.8, 2.4 Hz), 5.19 (s, 2 H), 3.39 (t, 2 H, J = 7.0 Hz), 3.29 (t, 2 H, J = 7.2 Hz), 2.11 (S, 3 H), 1.48-1.43 (M, 4 H), 1.29-1.20 (M, 4 H), 0.87 (t, 6 H, J = 7.2 Hz); MS eI m/z 510; IR (KBr) 3300, 2920, 2900, 2850, 1650, 1625, 1580 cm -1 ; CHN calc'd for C 33 H 38 N 2 O 3 . EXAMPLE 12 (E)-N-Butyl, N'-methyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=240-242°C; 1 H NMR (DMSO) 9.66 (s, 1 H), 8.70 (s, 1 H), 7.50 (d, 2 H, J = 8.1 Hz), 7.38-7.32 (m, 1 H), 7.16 (d, 2 H, J = 6.8 Hz), 7.06-7.01 (m, 2 H), 6.85-6.81 (m, 5 H), 6.57 (dd, 1 H, J = 8.6, 2.2 Hz), 5.19 (s, 2 H), 3.44, 3.33 (2 t, 2 H, J = 7.2 Hz), 3.06, 2.87 (2 s, 3 H), 2.11 (s, 3 H), 1.45 (m, 2 H), 1.24 (p, 2 H, J= 7.5 Hz), 0.87 (t, 3 H, J = 7.2 Hz); Ms eI m/z 468; IR (KBr) 3300, 1660, 1590 cm -1 ; CHN calc'd for C 30 H 32 N 2 O 3 + 0.2 H 2 O. EXAMPLE 13 (E)-Morpholino-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=165-167°C, 1 H NMR (DMSO) 9.66 (s, 1 H), 8.71 (s, 1 H), 7.52 (d, 2 H, J = 8.1 Hz), 7.39 (d, 1 H, J = 15.4 Hz), 7.15 (d, 2 H, J = 8.6 Hz), 7.12 (d, 1 H, J = 15.4 Hz), 7.06 (d, 1 H, J = 8.6 Hz), 6.85-6.81 (m, 5 H), 6.57 (dd, 1 H, J = 8.6, 2.2 Hz), 5.19 (s, 2 H), 3.65-3.64 (m, 2 H), 3.59-3.53 (m, 6 H), 2.11 (s, 3 H); IR (KBr) 3330, 1650, 1620, 1580 cm-1; MS (FAB) m/z 469 (M+H + ); CHN calc'd for C 29 H 28 N 2 O 4 + 0.5 H 2 O. EXAMPLE 14 (E)-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=161-163°C, 1 H NMR (DMSO) 9.65 (s, 1 H), 8.70 (s, 1 H), 7.48 (s, 1 H), 7.37 (d, 2 H, J = 8.35 Hz), 7.30 (d, 1 H, J = 15.8 Hz), 7.14 (d, 2 H, J = 8.35 Hz), 7.04 (d, 2 H, J = 8.6 Hz), 6.85-6.81 (m, 5 H), 6.57 (dd, 1 H, J = 8.8, 2.4 Hz), 6.48 (d, 1 H, J = 15.8 Hz), 5.18 (s, 2 H), 2.10 (s, 3 H); IR (KBr) 3320, 3180, 1660, 1580 cm -1 ; MS (FAB) m/z 399 (M+H + ); CHN calc'd for C 25 H 22 N 2 O 3 + 1.3 H 2 O. EXAMPLE 15 (E)-N, Methyl-3-{4-[5-hydroxy-2-(4-hydroxy-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=155-158°C; 1 H NMR (DMSO) 9.64 (s, 1 H), 8.70 (s, 1 H), 7.99 (q, 1 H, J = 4.4 Hz), 7.37 (d, 2 H, J = 8.1 Hz), 7.30 (d, 1 H, j = 15.8 Hz), 7.14 (d, 2 H, J = 8.6 Hz), 7.03 (d, 1 H, J = 8.6 Hz), 6.85-6.81 (m, 5 H), 6.57 (dd, 1 H, J = 8.6, 2.4 Hz), 6.48 (d, 1 H, J = 15.8 Hz), 5.18 (s, 2 H), 2.66 (d, 3 H, J = 4.6 Hz), 2.10 (s, 3 H); IR (KBr) 3400, 1660, 1620 cm-1; MS eI m/z 412; CHN calc'd for C 26 H 24 N 2 O 3 + 0.4 H 2 O. EXAMPLE 16 (E)-N, N-Dibutyl-3-{4-[5-hydroxy-2-(4-fluoro-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=180°C; 1 H NMR (DMSO) 8.77 (s, 1 H), 7.48 (d, 2 H, J = 8.4 Hz), 7.41-7.38 (m, 3 H), 7.38-7.29 (m, 3 H), 7.13 (d, 1 H, J = 8.8 Hz), 6.97 (d, 1 H, J = 15.4 Hz), 6.85 (d, 1 H, J = 2.4 Hz), 6.80 (d, 2 H, J = 8.1 Hz), 5.2 (s, 2 H), 3.40-3.36 (m, 2 H), 3.30-3.27 (m, 2 H), 2.10 (s, 3 H), 1.50-1.40 (m, 4 H), 1.29-1.21 (m, 4 H), 0.86 (t, 6 H, J = 7.2 Hz); IR (KBr) 3180, 2950, 2900, 2850, 1650, 1590 cm -1 ; MS eI m/z 512; CHN calcd for C 33 H 37 N 2 O 2 . EXAMPLE 17 (E)-N-Butyl, N'-Methyl-3-{4-[5-hydroxy-2-(4-fluoro-phenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide Mp=153-153.5°C; 1 H NMR (DMSO) 8.77 (s, 1 H), 7.50 (d, 2 H, J = 8.1 Hz), 7.42-7.36 (m, 2 H), 7.35-7.28 (m, 3 H), 7.13 (d, 1 H, J = 8.8 Hz), 7.03 (dd, 1 H, J = 15.4, 2.6 Hz), 6.84 (d, 1 H, J = 2.4 Hz), 6.80 (d, 2 H, J = 8.1 Hz), 6.62 (dd, 1 H, J = 8.8, 2.4 Hz), 5.21 (s, 2 H), 3.44, 3.41 (2 t, 2 H, J = 7.0 Hz), 3.06, 2.87 (2 s, 3 H), 2.10 (s, 3 H), 1.49-1.42 (m, 2 H), 1.27-1.20 (m, 2 H), 0.86 (t, 3 H); IR (KBr) 3300, 2950, 2860, 1645, 1580 cm -1 ; MS eI m/z 470; CHN calcd for C 30 H 31 FN 2 O 2 . EXAMPLE 18 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl-1H-indole A flask was charged with 4-benzyloxyaniline (45 g, 0.23 mol), 4'-benzyloxy-2-bromophenylpropiophenone (21g, 0.066 mol), and DMF (50 mL). The reaction was heated at reflux for 30 minutes and then cooled to rt and then partitioned between EtOAc (250 mL) and 1N HCl (aq) (100 mL). The EtOAc was washed with NaHCO 3 (aq) and brine, dried over MgSO 4 . The solution was concentrated and the residue taken up in CH 2 Cl 2 and hexanes added to precipitate out 25g of a crude solid. The solid was dissolved in CH 2 Cl 2 and evaporated onto silica gel and chromatographed using CH 2 Cl 2 /Hexane (1:5) to yield 9.2 g of a tan solid (33%): Mpt = 150-152°C; 1 H NMR (DMSO) 10.88 (s, 1 H), 7.56 (d, 2 H, J = 8.8 Hz), 7.48 (d, 4 H, J = 7.9 Hz), 7.42-7.29 (m, 6 H), 7.21 (d, 1 H, J = 7.0 Hz), 7.13 (d, 2 H, J = 8.8 Hz), 7.08 (d, 1 H, J = 2.2 Hz), 6.94 (dd, 1 H, J = 8.8, 2.4 Hz), 5.16 (s, 2 H), 5.11 (s, 2 H), 2.33 (s, 3 H); IR (KBr) 3470, 2880, 2820, 1620 cm -1 ; MS eI m/z 419. EXAMPLE 19 5-Benzyloxy-2-(4-benzyloxy-phenyl)-3-methyl)-1-ylmethyl-(4-phenyliodide)-indole A solution of 4 (3.0 g, 7.4 mmol) in DMF (25 mL) was treated with NaH (60% dispersion, 0.21 g, 8.9 mmol) and stirred at rt for 15 minutes. 4-iodobromobenzyl bromide (2.2 g, 7.4 mmol) was added and the reaction was stirred for 1 hour. The reaction mixture was poured into water and extracted with EtOAc, dried over MgSO 4 and concentrated. Trituration of the crude product with ether afforded 2.2 g of the product as a white solid: Mpt = 153-156°C; 1 H NMR (DMSO) 7.54 (d, 2 H, J = 8.6 Hz), 7.52-7.45 (m, 4 H), 7.37-7.29 (m, 6 H), 7.27 (d, 2 H, J = 8.8 Hz), 7:17 (d, 1 H, J = 9.0 Hz), 7.13 (d, 1 H, J = 2.2 Hz), 7.10 (d, 2 H, J = 8.8 Hz), 6.81 (dd, 1 H, J = 8.8, 2.4 Hz), 6.60 (d, 2 H, J = 8.3 Hz), 5.18 (s, 2 H), 5.12 (s, 2 H), 5.11 (s, 2 H), 2.15 (s, 3 H); MS eI m/z 635. EXAMPLE 20 2-(4-hydroxyphenyl)-3-methyl)-1-ylmethyl-(4-phenyliodide)-indole-5-ol A solution of 4 (2.2 g, 3.5 mmol) in CHCl 3 was treated with Iodotrimethylsilane (1.04 mL, 7.0 mmol) and the reaction was heated to reflux. After 2 h, an additional 3 eq of Iodotrimethylsilane was added and the reaction was stirred at rt for 18 h. The reaction was quenched by adding MeOH (5 mL). The organic layer was washed with an aqueous 10% solution of Na 2 SO 3 , HCI (1M) and dried over MgSO 4 . The solution was concentrated and chromatographed on silica gel EtOAc/hexane (3:7) to yield 4a as a foam (1.2 g): 1 H NMR 9.65 (s, 1 H), 8.71 (s, 1 H), 7.54 (d, 2 H, J = 8.3 Hz), 7.12 (d, 2 H, J = 8.3 Hz), 7.02 (d, 1 H, J = 8.6 Hz), 6.84-6.80 (m, 3 H), 6.61 (d, 2 H, J = 8.3 Hz), 6.57 (dd, 1 H, J = 6.4 Hz), 5.12 (s, 2 H), 2.09 (s, 3 H); MS eI m/z 455. General Procedure For Indole Propargylamine Preparation The title compounds of Examples 21-23 were produced using a solution containing a 10 fold molar excess of a secondary amine in DMF cooled to 0°C and treated with propargyl bromide (3 eq, 80% solution in toluene). After 1 h at 0°C, the reactions were allowed to rt for 1 h. The indole iodide (4a, 1 eq) was added followed by Cu(I)I (0.1 eq) and Pd(PPh 3 ) 2 Cl 2 (0.035 eq). The reaction mixture was then stirred 16-48 h and worked up by pouring into water and extracting into EtOAc. The EtOAc is concentrated and chromatographed on silica gel using EtOAc/hexane as eluting system. EXAMPLE 21 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(3-N, N- dimethyl-1-yl-prop-1-ynyl)-benzyl]-1H-indol-5-ol Mp=173-176°C; 1 H NMR (DMSO) 9.64 (s, 1 H), 8.70 (s, 1 H), 7.25 (d, 2 H, J = 8.1 Hz), 7.12 (d, 2 H, J = 8.3 Hz), 7.03 (d, 1 H, J = 8.6 Hz), 6.83-6.78 (m, 5 H), 6.57 (dd, 1 H, J = 8.8, 2.4 Hz), 5.17 (s, 2 H), 3.39 (s, 2 H), 2.19 (s, 6 H), 2.10 (s, 3 H); IR (KBr) 3390, 1490 cm -1 ; MS esI 411 (M+H + ). EXAMPLE 22 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(3-piperidin-1-yl-prop-1-ynyl)-benzyl]-1H-indol-5-ol Mp=118-123°C; 1 H NMR (DMSO) 9.65 (s, 1 H), 8.71 (s, 1 H), 7.24 (d, 2 H, J = 8.1 Hz), 7.12 (d, 2 H, J = 8.6 Hz), 7.02 (d, 1 H, J = 8.6 Hz), 6.83-6.80 (m, 5 H), 6.57 (dd, 1 H, J = 8.6, 2.2 Hz), 5.17 (s, 2 H), 3.39 (s, 2 H), 2.41 (m, 4 H), 2.10 (s, 3 H), 1.48 (p, 4 H, J = 5.7 Hz), 1.36-1.33 (m, 2 H); IR (KBr) 3400, 2920, 1620, 1420 cm -1 ; MS EI m/z 450; CHN calc'd for C 30 H 30 N 2 O 2 + 0.25 H 2 O EXAMPLE 23 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(3-pyrrolidin-1-yl-prop-1-ynyl)-benzyl]-1H-indol-5-ol (5c) Mp=174-176°C; 1H NMR (DMSO) 9.64 (s, 1 H), 8.70 (s, 1 H), 7.23 (d, 2 H, J = 8.3 Hz), 7.11 (d, 2 H, J = 8.6 Hz), 7.02 (d, 1 H, J = 8.8 Hz), 6.84 (m, 5 H), 6.57 (dd, 1 H, J = 8.6, 2.2 Hz), 5.17 (s, 2 H), 3.53 (s, 2 H), 2.53-2.51 (m, 4 H), 2.09 (s, 3 H), 1.69-1.66 (m, 4 H); IR (KBr) 3400, 2920, 2900, 1620 cm -1 ; MS eI m/z 436; CHN calcd for C 29 H 28 N 2 O 2 + 0.7 H 2 O. Biological Methods In vitro estrogen receptor binding assay Receptor preparation CHO cells overexpressing the estrogen receptor were grown in 150 mm 2 dishes in DMEM + 10% dextran coated charcoal, stripped fetal bovine serum. The plates were washed twice with PBS and once with 10mM Tris-HCl, pH 7.4, 1mM EDTA. Cells were harvested by scraping the surface and then the cell suspension was placed on ice. Cells were disrupted with a hand-held motorized tissue grinder using two, 10-second bursts. The crude preparation was centrifuged at 12,000g for 20 minutes followed by a 60 minute spin at 100,000g to produce a ribosome free cytosol. The cytosol was then frozen and stored at -80°C. Protein concentration of the cytosol was estimated using the BCA assay with reference standard protein. Binding assay conditions The competition assay was performed in a 96-well plate (polystyrene*) which binds <2.0% of the total input [ 3 H]-17β-estradiol and each data point was gathered in triplicate. 100uG/100uL of the receptor preparation was aliquoted per well. A saturating dose of 2.5 nM [ 3 H]17β-estradiol + competitor (or buffer) in a 50 uL volume was added in the preliminary competition when 100x and 500x competitor were evaluated, only 0.8 nM [ 3 H] 17β-estradiol was used. The plate was incubated at room temperature for 2.5 h. At the end of this incubation period 150 uL of ice-cold dextran coated charcoal (5% activated charcoal coated with 0.05% 69K dextran) was added to each well and the plate was immediately centrifuged at 99g for 5 minutes at 4°C. 200 uL of the supernatant solution was then removed for scintillation counting. Samples were counted to 2% or 10 minutes, whichever occurs first. Because polystyrene absorbs a small amount of [ 3 H]17β-estradiol, wells containing radioactivity and cytosol, but not processed with charcoal were included to quantitate amounts of available isotope. Also, wells containing radioactivity but no cytosol were processed with charcoal to estimate unremovable DPM of [ 3 H] 17β-estradiol. Corning #25880-96, 96-well plates were used because they have proven to bind the least amount of estradiol. Analysis of results Counts per minute (CPM) of radioactivity were automatically converted to disintegrated per minute (DPM) by the Beckman LS 7500 Scintillation Counter using a set of quenched standards to generate a H# for each sample. To calculate the % of estradiol binding in the presence of 100 or fold 500 fold competitor the following formula was applied: ((DPM sample-DPM not removed by charcoal) /(DPM estradiol-DPM not removed by charcoal)) x 100% = % of estradiol binding For the generation of IC 50 curves, % binding is plotted vs compound. IC 50 's are generated for compounds that show >30% competition at 500x competitor concentration. For a description of these methods, see Hulme, E.C., ed. 1992. Receptor-Ligand Interactions: A Practical Approach. IRL Press, New York.(see especially chapter 8). Ishikawa Cell Alkaline Phosphatase Assay Cell Maintenance and Treatment: Ishikawa cells were maintained in DMEM/F12 (50%:50%) containing phenol red + 10% fetal bovine serum and the medium was supplemented with 2 mM Glutamax, 1% Pen/Strap and 1 mM sodium pyruvate. Five days prior to the beginning of each experiment (treatment of cells) the medium was changed to phenol red-free DMEM/F12 + 10% dextran coated charcoal stripped serum. On the day before treatment, cells were harvested using 0.5% trypsin/EDTA and plated at a density of 5 X 10 4 cells/well in 96-well tissue culture plates. Test compounds were dosed at 10 -6 , 10 -7 and 10 -8 M in addition to 10 -6 M (compound) + 10 -9 M 17β- estradiol to evaluate the ability of the compounds to function as antiestrogens. Cells were treated for 48 h prior to assay. Each 96-well plate contained a 17β-estradiol control. Sample population for at each dose was n=8. Alkaline Phosphatase Assay: At the end of 48h the media is aspirated and cells are washed three times with phosphate buffered saline (PBS). 50µL of lysis buffer (0.1 M Tris-HCl, pH 9.8, 0.2% Triton X-100) is added to each well. Plates are placed at -80°C for a minimum of 15 minutes. Plates are thawed at 37°C followed by the addition of 150µL of 0.1 M Tris-HCl, pH 9.8, containing 4 mM para-nitrophenylphosphate (pNPP) to each well (final concentration, 3 mM pNPP). Absorbance and slope calculations were made using the KineticCalc Application program (Bio-Tek Instruments, Inc., Winooski, VT). Results are expressed as the mean +/- S.D. of the rate of enzyme reaction (slope) averaged over the linear portion of the kinetic reaction curve (optical density readings every 5 minutes for 30 minutes absorbance reading). Results for compounds are summarized as percent of response related to 1 nM 17β-estradiol. Various compounds were assayed for estrogenic activity by the alkaline phosphatase method and corresponding ED50 values (95% C.I.) were calculated. The four listed in the following were used as reference standards: 17β-estradiol 0.03 nM 17α-estradiol 1.42 nM estriol 0.13 nM estrone 0.36 nM A description of such methods is provided by Holinka, C.F., Hata, H., Kuramoto, H. and Gurpide, E. (1986) Effects of steroid hormones and antisteroids on alkaline phosphatase activity in human endometrial cancer cells (Ishikawa Line). Cancer Research, 46:2771-2774, and by Littlefield, B.A., Gurpide, E., Markiewicz, L., McKinley, B. and by Hochberg, R.B. (1990) A simple and sensitive microtiter plate estrogen bioassay based on stimulation alkaline phosphatase in Ishikawa cells; Estrogen action of D5 adrenal steroids. Endocrinology, 6:2757-2762. 2X VIT ERE Transfection Assay Cell Maintenance and Treatment Chinese Hamster Ovary cells (CHO) which had been stably transfected with the human estrogen receptor were maintained in DMEM + 10% fetal bovine serum (FBS). 48h prior to treatment the growth medium was replaced with DMEM lacking phenol red + 10% dextran coated charcoal stripped FBS (treatment medium). Cells were plated at a density of 5000 cells/well in 96-well plates containing 200 µL of medium/well. Calcium Phoshate Transfection Reporter DNA (Promega plasmid pGL2 containing two tandem copies of the vitellogenin ERE in front of the minimal thymidine kinase promoter driving the luciferase gene) was combined with the B-galactosidase expression plasmid pCH110 (Pharmacia) and carrier DNA (pTZ18U) in the following ratio: 10uG of reporter DNA 5uG of pCH110DNA 5 uG of pTZ18U 20 uG of DNA/1 mL of transfection solution The DNA (20uG) was dissolved in 500 uL of 250 mM sterile CaCl 2 and added dropwise to 500 uL of 2 X HeBS (0.28 M NaCl, 50 mM HEPES, 1.5 mM Na 2 HPO 4 , pH 7.05) and incubated at room temperature for 20 minutes. 20 uL of this mixture was added to each well of cells and remained on the cells for 16 h. At the end of this incubation the precipitate was removed, the cells were washed with media, fresh treatment media was replaced and the cells were treated with either vehicle, 1 nM 17β-estradiol, 1uM compound or 1 uM compound + 1 nM 17β-estradiol (tests for estrogen antagonism). Each treatment condition was performed on 8 wells (n=8) which were incubated for 24 h prior to the luciferase assay. Luciferase Assay After 24h exposure to compounds, the media was removed and each well washed with 2 X with 125 uL of PBS lacking Mg ++ and Ca ++ . After removing the PBS, 25 uL of Promega lysis buffer was added to each well and allowed to stand at room temperature for 15 min, followed by 15 min at -80°C and 15 min at 37°C. 20 uL of lysate was transferred to an opaque 96 well plate for luciferase activity evaluation and the remaining lysate (5 uL) was used for the B-galactosidase activity evaluation (normalize transfection). The luciferan substrate (Promega) was added in 100 uL aliquots to each well automatically by the luminometer and the light produced (relative light units) was read 10 seconds after addition. B-Galactosidase Assay To the remaining 5 uL of lysate 45 uL of PBS was added. Then 50 uL of Promega B-galactosidase 2X assay buffer was added, mixed well and incubated at 37°C for 1 hour. A plate containing a standard curve (0.1 to 1.5 milliunits in triplicate) was set up for each experimental run. The plates were analyzed on a Molecular Devices spectrophotometric plate reader at 410 nm. The optical densities for the unknown were converted to milliunits of activity by mathematical extrapolation from the standard curve. Analysis of Results The luciferase data was generated as relative light units (RLUs) accumulated during a 10 second measurement and automatically transferred to a JMP (SAS Inc) file where background RLUs were subtracted. The B-galactosidase values were automatically imported into the file and these values were divided into the RLUs to normalize the data. The mean and standard deviations were determined from a n=8 for each treatment. Compounds activity was compared to 17β-estradiol for each plate. Percentage of activity as compared to 17β-estradiol was calculated using the formula %=((Estradiol-control)/(compound value)) X 100. These techniques are described by Tzukerman, M.T., Esty, A., Santiso-Mere, D., Danielian, P., Parker, M.G., Stein, R.B., Pike, J.W. and McDonnel, D.P. (1994). Human estrogen receptor transactivational capacity was determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions (see Molecular Endocrinology, 8:21-30). Rat Uterotrophic/Antiuterotrophic Bioassay The estrogenic and antiestrogenic properties of the compounds were determined in an immature rat uterotrophic assay (4 day) that (as described previously by L.J.Black and R.L.Goode, Life Sciences, 26, 1453 (1980)). Immature Sprague-Dawley rats (female, 18 days old) were tested in groups of six. The animals were treated by daily ip injection with 10 uG compound, 100 uG compound, (100 uG compound + 1 uG 17β-estradiol) to check antiestrogenicity, and 1 uG 17β-estradiol, with 50% DMSO/50% saline as the injection vehicle. On day 4 the animals were sacrificed by CO 2 asphyxiation and their uteri were removed and stripped of excess lipid, any fluid removed and the wet weight determined. A small section of one horn was submitted for histology and the remainder used to isolate total RNA in order to evaluate complement component 3 gene expression. Biological Results Estrogen Receptor Affinity (reported as RBA: 17β-estradiol=100) Compound RBA raloxifene 200 tamoxifen 1.8 Example 10 20 Example 7 42 Example 8 40 Example 9 40 Example 12 114 Example 11 80 Example 13 27 Example 14 32 Example 15 53 Example 21 53 Example 22 23 Infection Luciferase Assay Compound % Activation % Activation with 1 nM 17β-estradiol 17β-estradiol 100% N/A estriol 38% N/A tamoxifen 0% 10% raloxifene 0% 0% Example 10 1% 2% Example 7 4% 8% Example 8 6% 78% Example 9 6% 8% Example 12 13% 24% Example 11 8% 12% Example 13 8% 17% Example 14 19% 57% Example 15 15% 31% Example 21 34% 34% Example 22 17% 19% Ishikawa Alkaline Phosphatase Assay Compound % Activation % Activation (Compound + 1 nM 17β-estradiol) 17β-estradiol 100% N/A tamoxifen 0% 45% raloxifen 5% 5% Example 10 6% 19% Example 7 1% 9% Example 8 10% 22% Example 9 3% 11% Example 12 7% 16% Example 11 6% 11% Example 13 7% 9% Example 14 2% 14% Example 15 0% 5% Example 21 34% 34% Example 22 27% 23% 3-Day Ovariectomized Rat Model Compound 10µG 100µG Tamoxifen 69.6 mg 71.4 mg Raloxifen 47.5 mg 43.2 mg control = 42.7 mg 1 µG 17β-estradiol = 98.2 Compound 10µG 100µG 100µG plus 1µG 17β-Estradiol Example 7 47.8 mg 64.8 mg 75.4 control = 20.2 mg 1 µG 17β-estradiol = 80.2 mg Compound 10µG 100µG 100µG plus 1µG 17β-Estradiol Example 12 36.9 mg 49.5 mg 63.1 control = 31.4 mg 1 µG 17β-estradiol = 89.0 mg Compound 10µG 100µG 100µG plus 1µG 17β-Estradiol Example 11 39.3 mg 59.8 mg 81.0 mg control = 24.5 mg 1 µG 17β-estradiol = 90.8 mg Compound 10µG 100µG 100µG plus 1µG 17β-Estradiol Example 14 32.5 mg 56.4 mg 79.8 mg Example 15 40.4 mg 56.3 mg 69.3 mg control = 29.1 mg 1 µg 17β-estradiol = 95.5 mg Compound 10µG 100µG 100µG + 1µG 17β-estradiol Example 21 56.0 mg 84.0 mg 77.6 mg control = 32.1 mg 1 µG 17β-estradiol = 90.2 mg Example 22 55.6 mg 71.3 mg 66.8 mg control = 21.7 mg 1 µg 17β-estradiol = 82.8 mg

Claims: A compound having the structure: wherein: R 1 is selected from H, OH or the C 1 -C 4 esters or alkyl ethers thereof, or halogen; R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from H, OH or the C 1 -C 4 esters or alkyl ethers thereof, halogen, cyano, C 1 -C 6 alkyl or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; n is 2 or 3; X is selected from H, C 1 -C 6 alkyl, cyano, nitro, trifluoromethyl, halogen; Z is selected from Y is selected from: a) the moiety wherein R 7 and R 8 are independently selected from the group of H, C 1 -C 6 alkyl, phenyl or combined by -(CH 2 ) p -, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, -CO 2 H, -CN, -CONH(C 1 -C 4 ) alkyl, -NH 2 , C 1 -C 4 alkylamino, di(C 1 -C 4 ) alkylamino, -NHSO 2 (C 1 -C 4 ) alkyl, -NHCO(C 1 -C 4 ) alkyl, and -NO 2 . b) a five-, six-, or seven-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C 1 -C 4 alkyl)-, -N=, and -S(O) m -, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 acyloxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy(C 1 -C 4 )alkyl, -CO 2 H, -CN, -CONHR 1 , -NH 2 , (C 1 -C 4 ) alkylamino, di-(C 1 -C 4 alkyl)amino, -NHSO 2 R 1 , -NHCOR 1 , -NO 2 and phenyl optionally substituted with from 1 to 3 (C 1 -C 4 )alkyl groups; c) a bicyclic ring system consisting of a five or six-membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group of -O-, -NH-, -N(C 1 C 4 alkyl)-, and -S(O) m -, wherein m is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 acyloxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy (C 1 -C 4 )alkyl, -CO 2 H, -CN, -CONHR 1 , -NH 2 , (C 1 -C 4 )alkylamino, di-(C 1 -C 4 alkyl)amino, -NHSO 2 R 1 , -NHCOR 1 , -NO 2 and phenyl optionally substituted with from 1 to 3 (C 1 -C 4 )alkyl groups; or a pharmaceutically acceptable salt thereof. A compound of Claim 1 wherein: R 1 is selected from H, OH or the C 1 -C 4 esters or alkyl ethers thereof, halogen; R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from H, OH or the C 1 -C 4 esters or alkyl ethers thereof, halogen, cyano, C 1 -C 6 alkyl, or trifluoromethyl, with the proviso that, when R 1 is H, R 2 is not OH; X is selected from H, C 1 -C 6 alkyl, cyano, nitro, triflouromethyl, halogen; Y is the moiety R 7 and R 8 are selected independently from H, C 1 -C 6 alkyl, or combined by -(CH 2 ) p -, wherein p is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from hydroxyl, halo, C 1 -C 4 alkyl, trihalomethyl, C 1 -C 4 alkoxy, trihalomethoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl, C 1 -C 4 alkylsulfonyl, hydroxy(C 1 -C 4 )alkyl, -CO 2 H, -CN,-CONH(C 1 -C 4 ) alkyl, -NH 3 , C 1 -C 4 alkylamino, C 1 -C 4 dialkylamino, -NHSO 2 (C 1 -C 4 ) alkyl, -NHCO(C 1 -C 4 ) alkyl, and -NO 2 . A compound of Claim 3 wherein R 7 and R 8 are concatenated together as-(CH 2 ) p - to form a ring, wherein p is an integer of from 2 to 6, the ring being optionally substituted with 1-3 substituents selected from the group of C 1 -C 3 alkyl, trifluoromethyl, halogen, hydrogen, phenyl, nitro, or -CN. A compound of Claim 1 which is one of the following: (E)-N,N-Diethyl-3- {4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide; 1(E)-N-tert-butyl-3-{4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide; (E)-Pyrrolidino-3-{4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide; (E)-N,N-Dimethyl-3- {4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide; (E)-N,N-Dibutyl-3- {4- [5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide; (E)-N-Butyl,N'-methyl-3-{4- [5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide; (E)-Morpholinino-3- 4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-indol-1-ylmethyl]-phenyl}acrylamide; (E)-3-{4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-indol-1-ylmethyl]-phenyl}-acrylamide; (E)-N,Methyl-3-{4-[5-hydroxy-2-(4-hydroxyphenyl)-3-methyl-indol-1-ylmethyl]-phenyl}acrylamide; (E)-N,N-Dibutyl-3-{4-[5-hydroxy-2-(4-fluorophenyl)-3-methyl-indol-1-ylmethyl]-phenyl}acrylamide; (E)-N-Butyl,N'-Methyl-3-{4-[5-hydroxy-2-(4-fluorophenyl)-3-methyl-indol-1-ylmethyl]phenyl}acrylamide; 2-(4-Hydroxyphenyl)-3-methyl-1-[4-(3-N,N-dimethyl-1-yl-prop-1-ynyl)benzyl]-1H-indol-5-ol; 2-(4-Hydroxyphenyl)-3-methyl-1-[4-(3-piperidin-1-ylprop-1-ynyl)benzyl]-1H-indol-5-ol or 2-(4-Hydroxyphenyl)-3-methyl-1-[4-(3-pyrrolidin-1-ylprop-1-ynyl)benzyl]-lH-indol-5-ol; or a pharmaceutically acceptable salt thereof. Use of a compound according to any one of Claims 1 to 4 in the preparation of a medicament for treating or preventing bone loss in a mammal. Use of a compound according to any of Claims 1 to 4 in the preparation of a medicament for treating or preventing disease states or syndromes which are caused or associated with an estrogen deficiency in a mammal. Use of a compound as claimed in anyone of Claims 1 to 4 in the preparation of a medicament for treating or preventing cardiovascular disease in a mammal, the method comprising administering to a mammal. A compound according to anyone of Claims 1 to 4 for use as a medicament. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. A process for preparing a compound of formula I which comprises one of the following: a) reacting a compound of formula wherein R 1 -R 6 and X are as defined in Claim 1 with an acrylamide of formula wherein Y is as defined in Claim 1 to give a compound of formula I wherein Z is-CH=CH-COY; or b) reacting a compound of formula wherein R 1 -R 6 and X are as defined in Claim 1 with a compound of formula wherein n and Y are as defined in Claim 1 to give a corresponding compound of Formula I wherein Z is ―C≡C―(CH 2 ) n ―Y.

Inventors: COLLINI MICHAEL D, MILLER CHRIS P, TRAN BACH D, COLLINI, MICHAEL D., MILLER, CHRIS P., TRAN, BACH D.
Applicants: WYETH CORP, WYETH
Application year: 1997
Main classification: C07D209
IPC codes: C07D209, A61K31, C07D403, A61P15, A61P19, C07D413